Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11111147 | 0.95 | MEN1 (0.59) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL3454654 | 0.93 | MEN1 (0.73) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL20681358 | 0.93 | MEN1 (0.54) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL25945154 | 0.91 | MEN1 (0.70) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL4878423 | 0.88 | MEN1 (0.67) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL21810615 | 0.86 | MEN1 (0.50) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL8284440 | 0.85 | MEN1 (0.69) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL15549968 | 0.79 | MEN1 (1.00) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL20681295 | 0.76 | GRIN2D (0.46) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL28655417 | 0.76 | HSD17B1 (0.65) | MEN1MAPK1KMT2ANPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867231-B1 | NOVEL PROCESSES | INFLAZOME LTD (IE) | 2024-05-01 | — | — | EP | claimed |
| US-11724988-B2 | Processes | INFLAZOME LIMITED (IE) | 2023-08-15 | — | — | US | claimed |
| US-20220064125-A1 | NOVEL PROCESSES | INFLAZOME LIMITED (IE) | 2022-03-03 | — | — | US | claimed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4034579-B1 | CATALYSTS | BOREALIS AG (AT) | 2025-07-23 | — | — | EP | disclosed |
| US-12319772-B2 | Catalysts | BOREALIS AG (AT) | 2025-06-03 | — | — | US | disclosed |
| CN-119823022-A | NLRP3 small-molecule protein degradation agent and preparation method and application thereof | 复旦大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0923589-A1 | 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1998006727-A1 | 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0039025-B1 | DERIVATIVES OF ARYL KETONES AS SENSITIZERS OF PHOTOPOLYMERIZABLE COMPOUNDS FOR THE VISIBLE SPECTRAL RANGE, AND PHOTOPOLYMERIZABLE COMPOSITIONS COMPRISING THE SAID SENSITIZERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4351893-A | TRIARYLIMIDAZOLE DIMER INITIATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| EP-0039025-A1 | Derivatives of aryl ketones as sensitizers of photopolymerizable compounds for the visible spectral range, and photopolymerizable compositions comprising the said sensitizers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319772-B2 | Catalysts | SIGMAR1, C1S, CYCS | MEN1 1417/4885MAPK1 2399/4885KMT2A 1180/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | MEN1 4299/4885MAPK1 1095/4885KMT2A 3993/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | MEN1 3166/4885MAPK1 2556/4885KMT2A 1500/4885 |
| US-20220064125-A1 | NOVEL PROCESSES | NLRP3, NOD1, NLRP1 | MEN1 4329/4885MAPK1 1614/4885KMT2A 4832/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MEN1 3390/4885MAPK1 1647/4885KMT2A 4441/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3390/4885MAPK1 1647/4885KMT2A 4441/4885 |
| US-11724988-B2 | Processes | NLRP3, NOD1, NLRP1 | MEN1 3749/4885MAPK1 1548/4885KMT2A 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.